Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study

Table 3 Logistic regression: Predictive factors for response to IFX induction therapy at week 12 in Crohn's disease

Factor	Coefficient	Pvalue	OR	95% CI
Gender	0,070	0.828	-	-
Longer disease duration (≤ 10 years vs. > 10 years)	-1.161	< 0.001	0.349	0.165-0.596
Disease behavior	-0,312	0.349	-	-
Concomitant AZA/methotrexate use	0.710	0.05	2.03	1.001-4.168
Steroid use	-0,438	0.184	-	-

The coefficient is equivalent to the natural log of the OR; p value: level of significance;
OR: odds ratio; 95% CI: 95% confidence interval.

ISSN: 1471-230X